Fujian Wanchen Biotechnology Co. Ltd (300972) - Net Assets
Based on the latest financial reports, Fujian Wanchen Biotechnology Co. Ltd (300972) has net assets worth CN¥2.32 Billion CNY (≈ $338.97 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.46 Billion ≈ $1.09 Billion USD) and total liabilities (CN¥5.14 Billion ≈ $752.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Fujian Wanchen Biotechnology Co. Ltd (300972) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.32 Billion |
| % of Total Assets | 31.05% |
| Annual Growth Rate | 33.47% |
| 5-Year Change | 264.74% |
| 10-Year Change | N/A |
| Growth Volatility | 41.69 |
Fujian Wanchen Biotechnology Co. Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Fujian Wanchen Biotechnology Co. Ltd total assets for the complete picture of this company's asset base.
Annual Net Assets for Fujian Wanchen Biotechnology Co. Ltd (2019–2024)
The table below shows the annual net assets of Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2024. For live valuation and market cap data, see Fujian Wanchen Biotechnology Co. Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.46 Billion ≈ $213.84 Million |
+110.02% |
| 2023-12-31 | CN¥695.81 Million ≈ $101.82 Million |
+3.49% |
| 2022-12-31 | CN¥672.36 Million ≈ $98.39 Million |
+3.01% |
| 2021-12-31 | CN¥652.71 Million ≈ $95.51 Million |
+62.91% |
| 2020-12-31 | CN¥400.65 Million ≈ $58.63 Million |
+16.19% |
| 2019-12-31 | CN¥344.82 Million ≈ $50.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fujian Wanchen Biotechnology Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 253.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥346.19 Million | 31.52% |
| Other Components | CN¥751.96 Million | 68.48% |
| Total Equity | CN¥1.10 Billion | 100.00% |
Fujian Wanchen Biotechnology Co. Ltd Competitors by Market Cap
The table below lists competitors of Fujian Wanchen Biotechnology Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lear Corporation
NYSE:LEA
|
$6.35 Billion |
|
SICC Co. Ltd.
SHG:688234
|
$6.35 Billion |
|
Jiangxi Copper Company Limited
F:JIX
|
$6.35 Billion |
|
Engie Brasil Energia S.A
F:7TE1
|
$6.35 Billion |
|
Astor Enerji AS
IS:ASTOR
|
$6.35 Billion |
|
Beijing Enlight Media
SHE:300251
|
$6.34 Billion |
|
Guangzhou Great Power Energy&Technology Co Ltd
SHE:300438
|
$6.34 Billion |
|
Archrock Inc
NYSE:AROC
|
$6.33 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fujian Wanchen Biotechnology Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 645,361,196 to 1,098,154,172, a change of 452,792,976 (70.2%).
- Net income of 293,522,037 contributed positively to equity growth.
- Dividend payments of 29,955,363 reduced retained earnings.
- Other factors increased equity by 189,226,301.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥293.52 Million | +26.73% |
| Dividends Paid | CN¥29.96 Million | -2.73% |
| Other Changes | CN¥189.23 Million | +17.23% |
| Total Change | CN¥- | 70.16% |
Book Value vs Market Value Analysis
This analysis compares Fujian Wanchen Biotechnology Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 37.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 75.73x to 37.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.00 | CN¥226.81 | x |
| 2020-12-31 | CN¥3.48 | CN¥226.81 | x |
| 2021-12-31 | CN¥4.25 | CN¥226.81 | x |
| 2022-12-31 | CN¥4.35 | CN¥226.81 | x |
| 2023-12-31 | CN¥4.17 | CN¥226.81 | x |
| 2024-12-31 | CN¥6.10 | CN¥226.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fujian Wanchen Biotechnology Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 26.73%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.91%
- • Asset Turnover: 4.46x
- • Equity Multiplier: 6.61x
- Recent ROE (26.73%) is above the historical average (12.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 26.74% | 20.44% | 0.69x | 1.90x | CN¥57.71 Million |
| 2020 | 23.99% | 21.36% | 0.68x | 1.64x | CN¥56.06 Million |
| 2021 | 3.59% | 5.39% | 0.50x | 1.32x | CN¥-41.82 Million |
| 2022 | 7.14% | 8.69% | 0.46x | 1.80x | CN¥-19.08 Million |
| 2023 | -12.85% | -0.89% | 2.37x | 6.08x | CN¥-147.46 Million |
| 2024 | 26.73% | 0.91% | 4.46x | 6.61x | CN¥183.71 Million |
Industry Comparison
This section compares Fujian Wanchen Biotechnology Co. Ltd's net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $1,296,219,565
- Average return on equity (ROE) among peers: -3.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fujian Wanchen Biotechnology Co. Ltd (300972) | CN¥2.32 Billion | 26.74% | 2.22x | $6.35 Billion |
| ShenZhen Kondarl Group Co Ltd (000048) | $2.66 Billion | 29.04% | 5.59x | $1.14 Billion |
| Guangdong Guanghong Holdings Co Ltd (000529) | $396.79 Million | -213.77% | 2.82x | $483.52 Million |
| Hunan Zhenghong Science and Technology Develop Co Ltd (000702) | $46.46 Million | 57.45% | 1.07x | $361.65 Million |
| Hefei Fengle Seed Co Ltd (000713) | $96.90 Million | 39.05% | 0.20x | $759.23 Million |
| Luoniushan Co Ltd (000735) | $1.83 Billion | 3.32% | 1.46x | $1.11 Billion |
| New Hope Liuhe Co Ltd (000876) | $1.84 Billion | 6.76% | 0.76x | $5.75 Billion |
| Yuan Longping High-tech Agriculture Co Ltd (000998) | $831.50 Million | 4.85% | 0.18x | $1.97 Billion |
| Dongrui Food Group Co Ltd (001201) | $322.80 Million | 16.01% | 0.89x | $499.06 Million |
| Jiangxi Sunshine Dairy Co Ltd (001318) | $1.27 Billion | 8.70% | 0.07x | $552.18 Million |
| Shandong Denghai Seeds Co Ltd (002041) | $3.66 Billion | 12.08% | 0.22x | $1.32 Billion |
About Fujian Wanchen Biotechnology Co. Ltd
Fujian Wanchen Food Group Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, production, and sale of edible fungi in China and internationally. The company provides enoki and golden enoki, white jade, crab, seafood, deer antler, oyster, and other mushrooms products, as well as flammulina velutipes, hydrangea edulis, and pleurotus eryngii. It is also invo… Read more